Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 14/20 | 0.73 |
| ▸ | IMPDH1 | P20839 | 4/20 | 0.73 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250135 | 0.89 | IMPDH2 (0.73) | IMPDH2IMPDH1MEN1ALDH1A1MAPT | |
| SCHEMBL14065059 | 0.85 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7209044 | 0.84 | IMPDH2 (0.79) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL14293547 | 0.82 | IMPDH2 (0.76) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12343257 | 0.82 | IMPDH2 (0.76) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7729166 | 0.82 | IMPDH2 (0.57) | IMPDH2IMPDH1AAK1ROCK2ROCK1 | |
| SCHEMBL7214976 | 0.81 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7215018 | 0.81 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12749617 | 0.81 | IMPDH2 (0.89) | IMPDH2IMPDH1AAK1ROCK2ROCK1 | |
| SCHEMBL30292051 | 0.81 | IMPDH2 (0.60) | IMPDH2IMPDH1AAK1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329681-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| US-6617323-B2 | For therapy and prophylaxis of transplant rejection and autoimmune diseases | BRISTOL-MYERS SQUIBB CO. | 2003-09-09 | — | — | US | disclosed |
| US-20020183315-A1 | Amino-substituted compounds useful as inhibitors of impdh enzyme | IWANOWICZ EDWIN J (US) | 2002-12-05 | — | — | US | disclosed |
| US-6420403-B1 | INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE, TRANSPLANT REJECTION AND AUTOIMMUNE DISEASES. | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183315-A1 | Amino-substituted compounds useful as inhibitors of impdh enzyme | IMPDH1, IMPDH2, ALDH7A1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.